IP Topics
By
Steven J. Lee, Ph.D.,
Richard L. DeLucia and Ashton J. Delauney, Ph.D.
- May 2010
This article first appeared in the 2010 edition of IAM Life Sciences 250.
The Waxman-Hatch Act offers opportunities to manufacturers of both brand and generic drugs in terms of market entry and exclusivity periods. A canny and fluid litigation strategy can help parties to take best advantage of the provisions available.